Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach

被引:112
|
作者
Ito, K
Kusuhara, H
Sugiyama, Y
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[2] Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan
关键词
oral absorption; CYP3A4; P-glycoprotein; diffusion model; drug interaction;
D O I
10.1023/A:1018872207437
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To evaluate the effects of gut metabolism and efflux on drug absorption by simulation studies using a pharmacokinetic model involving diffusion in epithelial cells. Methods. A pharmacokinetic model for drug absorption was constructed including metabolism by CYP3A4 inside the epithelial cells, P-gp-mediated efflux into the lumen, intracellular diffusion from the luminal side to the basal side, and subsequent permeation through the basal membrane. Partial differential equations were solved to yield an equation for the fraction absorbed from gut to the blood. Effects of inhibition of CYP3A4 and/or P-gp on the fraction absorbed were simulated for a hypothetical substrate for both CYP3A4 and P-gp. Results. The fraction absorbed after oral administration was shown to increase following inhibition of P-gp. This increase was more marked when the efflux clearance of the drug was greater than the sum of the metabolic and absorption clearances and when the intracellular diffusion constant was small. Furthermore, it was demonstrated that the fraction absorbed was synergistically elevated by simultaneous inhibition of both CYP3A4 and P-gp. Conclusions. The analysis using our present diffusion model is expected to allow the prediction of in vivo intestinal drug absorption and related drug interactions from in vitro studies using human intestinal microsomes, gut epithelial cells, CYP3A4-expressed Caco-2 cells, etc.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 50 条
  • [1] Effects of Intestinal CYP3A4 and P-Glycoprotein on Oral Drug Absorption—Theoretical Approach
    Kiyomi Ito
    Hiroyuki Kusuhara
    Yuichi Sugiyama
    Pharmaceutical Research, 1999, 16 : 225 - 231
  • [2] Functional interaction of intestinal CYP3A4 and P-glycoprotein
    Kivistö, KT
    Niemi, M
    Fromm, MF
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 (06) : 621 - 626
  • [3] Predicting Drug-Drug Interactions Involving the Inhibition of Intestinal CYP3A4 and P-Glycoprotein
    Tachibana, Tatsuhiko
    Kato, Motohiro
    Takano, Junichi
    Sugiyama, Yuichi
    CURRENT DRUG METABOLISM, 2010, 11 (09) : 762 - 777
  • [4] The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4
    Wang, Xianming
    Zhang, Xiang
    Huang, Xinhui
    Li, Yuntong
    Wu, Mengchao
    Liu, Jingfeng
    XENOBIOTICA, 2016, 46 (07) : 651 - 658
  • [5] Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein
    Tachibana, T.
    Kato, M.
    Watanabe, T.
    Mitsui, T.
    Sugiyama, Y.
    XENOBIOTICA, 2009, 39 (06) : 430 - 443
  • [6] Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients
    Gallo, Paolo
    De Vincentis, Antonio
    Pedone, Claudio
    Nobili, Alessandro
    Tettamanti, Mauro
    Gentilucci, Umberto Vespasiani
    Picardi, Antonio
    Mannucci, Pier Mannuccio
    Incalzi, Raffaele Antonelli
    Prisco, Domenico
    Silvestri, Elena
    Emmi, Giacomo
    Bettiol, Alessandra
    Caterina, Cenci
    Biolo, Gianni
    Zanetti, Michela
    Guadagni, Martina
    Zaccari, Michele
    Chiuch, Massimiliano
    Vanoli, Massimo
    Grignani, Giulia
    Pulixi, Edoardo Alessandro
    Bernardi, Mauro
    Bassi, Silvia Li
    Santi, Luca
    Zaccherini, Giacomo
    Lupattelli, Graziana
    Mannarino, Elmo
    Bianconi, Vanessa
    Paciullo, Francesco
    Alcidi, Riccardo
    Nuti, Ranuccio
    Valenti, Roberto
    Ruvio, Martina
    Cappelli, Silvia
    Palazzuoli, Alberto
    Girelli, Domenico
    Busti, Fabiana
    Marchi, Giacomo
    Barbagallo, Mario
    Dominguez, Ligia
    Cocita, Floriana
    Beneduce, Vincenza
    Plances, Lidia
    Corrao, Salvatore
    Natoli, Giuseppe
    Mularo, Salvatore
    Raspanti, Massimo
    Cavallaro, Federica
    Zoli, Marco
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2019, 65 : 51 - 57
  • [7] Effects of clarithromycin on the pharmacokinetics of tacrolimus and expression of CYP3A4 and P-glycoprotein in rats
    Wen, Jinhua
    ChenYang, Menghua
    Zhao, Menghua
    Hu, Weiqiang
    Xiao, Yu Wei
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 (04) : 843 - 848
  • [8] Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans
    Hajda, Jacek
    Rentsch, Katharina M.
    Gubler, Christoph
    Steinert, Hans
    Stieger, Bruno
    Fattinger, Karin
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 41 (05) : 729 - 735
  • [9] Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension
    Xiaoyu Sun
    Shunxiong Tang
    Binbin Hou
    Zhijun Duan
    Zhen Liu
    Yang Li
    Shoucheng He
    Qiuming Wang
    Qingyong Chang
    BMC Gastroenterology, 21
  • [10] The barrier function of CYP3A4 and P-glycoprotein in the small bowel
    Watkins, PB
    ADVANCED DRUG DELIVERY REVIEWS, 1997, 27 (2-3) : 161 - 170